Optimization of antimicrobial dosing in accordance with pharmacokinetics/
pharmacodynamics targets can improve survival and clinical cure. Dosing regimens for …

In patients that are admitted to intensive care units (ICUs), the clinical outcome of severe
infections depends on several factors, as well as the early administration of chemotherapies …

Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new
antibiotics against Pseudomonas aeruginosa infections. Data from in vitro assays of CZA …

Amikacin has been one of the important antimicrobial agents against Gram-negative
pathogens. However, there is discrepancy regarding the amikacin initial dosage, with some …

Objectives Broad-spectrum antimicrobial resistance in Pseudomonas aeruginosa (PSA)
isolates is a growing concern as our therapeutic options have become significantly limited …

Introduction: Classically, aminoglycosides are known to have low penetration into the lung
tissue. So far, no study has been conducted on human adult patients to evaluate amikacin …

Relebactam is a novel class A/C β-lactamase inhibitor that restores imipenem in vitro activity
against multidrug-resistant and carbapenem-nonsusceptible Pseudomonas aeruginosa …

Aims Modifications of antimicrobials' pharmacokinetic parameters have been reported in
critically ill patients, resulting in a risk of treatment failure. We characterized amikacin …

Combination therapy is an attractive option for the treatment of multidrug-resistant (MDR)
Pseudomonas aeruginosa infections; however, limited data are available on combinations …

Background Extensively drug-resistant (XDR) Pseudomonas aeruginosa (P. aeruginosa)
and particularly P. aeruginosa high-risk clones, are of growing concern because treatment …